Tag: Siltuximab [Sylvant]

By Posted on Posted in New Drug Approval, Personalized Medicine, Rare Diseases Tagged with , , , , , , ,

April 23, 2014 – The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes). MCD causes an abnormal overgrowth of immune …

FDA approves Siltuximab [Sylvant] for rare Castleman’s disease Read more »

By Posted on Posted in New Drug Approval Tagged with , , , , , ,

On 20 March 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sylvant, 100 mg and 400 mg, Powder for concentrate for solution for …

EMA: Granting of a marketing authorisation for the medicinal product Siltuximab [Sylvant] for the treatment of multicentric Castleman’s Disease (MCD) recommended. Read more »